Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Nearly 3.8 million Canadians live with asthma and approximately 8% of these patients have severe disease, suffering from frequent exacerbations and leading to increased healthcare costs [1, 2]. In Canada, adult patients with severe eosinophilic asthma who are inadequately controlled on standard therapy may be eligible for treatment with a biologic [3]. Biologic treatments target inflammatory pathways involved in asthma pathogenesis, predominantly endotypes with type 2 inflammation [3, 4]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. S.G. Noorduyn is an AstraZeneca Canada employee. K. Johnston reports funding from AstraZeneca Canada to their employer (Broadstreet Health Economics & Outcomes Research) to support the conduct of this work. K. Osenenko reports funding from AstraZeneca Canada to their employer (Broadstreet Health Economics & Outcomes Research) to support the conduct of this work. N. Sriskandarajah is an AstraZeneca employee. A. Gendron is an AstraZeneca employee with access to stock. L. Mbuagbaw reports consulting fees from AstraZeneca for study design and analysis.